Table 2 Characteristic features of liver pathology and NAFLD activity score according to the AMLN diet and DPP4i administration at 20th week.

From: Dipeptidyl peptidase-4 inhibitor protects against non-alcoholic steatohepatitis in mice by targeting TRAIL receptor-mediated lipoapoptosis via modulating hepatic dipeptidyl peptidase-4 expression

 

Chow

AMLN

AMLN + DPP4i

N = 10

N = 13

N = 10

Steatosis

0.7 ± 0.5

2.8 ± 0.4*

1.9 ± 0.9*#

Lobular inflammation

0.1 ± 0.3

1.8 ± 0.6*

1.1 ± 0.7*#

Hepatocyte ballooning

0.8 ± 0.4

1.6 ± 0.5*

1.3 ± 0.5*

NAFLD activity score

1.6 ± 0.7

6.2 ± 1.3*

4.3 ± 1.9*#

  1. Data are presented as mean ± SEM. *p < 0.05 versus vehicle-treated chow-fed mice. #p < 0.05 versus vehicle-treated AMLN-fed mice. Chow, vehicle-treated chow-fed mice; AMLN, vehicle-treated AMLN-fed mice; AMLN + DPP4i, DPP4i-treated (teneligliptin 20 mg/kg of body weight/day by oral gavage for 10 weeks) AMLN-fed mice.
  2. AMLN, Amylin liver NASH model diet; DPP4i, dipeptidyl peptidase-4 inhibitors; NAFLD, non-alcoholic fatty liver disease.
Back to article page